Obesity Clinical Trial
Official title:
Combined Treatment With PDE-4 Inhibitor Roflumilast and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome
Verified date | January 2014 |
Source | University Medical Centre Ljubljana |
Contact | n/a |
Is FDA regulated | No |
Health authority | Slovenia: Ethics Committee |
Study type | Interventional |
The purpose of this study was to determine whether combined treatment with phosphodiesterase-4 (PDE-4) inhibitor roflumilast and metformin is more effective than metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome (PCOS) who had been previously poor responders regarding weight reduction on metformin monotherapy. The investigators anticipated greater changes in body weight in patients on combined treatment than in those on monotherapy with metformin.
Status | Completed |
Enrollment | 36 |
Est. completion date | January 2014 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - 18 years old to menopause - polycystic ovary syndrome (NICHD criteria) - BMI of 30 kg/m² or higher Exclusion Criteria: - depression - type 1 or type 2 diabetes mellitus - history of carcinoma - Cushing's syndrome or congenital (non-classic) adrenal hyperplasia - significant cardiovascular, kidney or hepatic disease - the use of medications other than metformin known or suspected to affect reproductive or metabolic functions - the use of statins, within 90 days prior to study entry |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Slovenia | University Medical Center Ljubljana | Ljubljana |
Lead Sponsor | Collaborator |
---|---|
University Medical Centre Ljubljana |
Slovenia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The other outcomes was changes in fasting concentrations of glucose. | Patient's blood was drawn between 8 and 9 a.m. Concentrations of fasting glucose was measured in mmol/L. | Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial. | No |
Other | Other outcome was change in fasting concentration of insulin. | Patient's blood was drawn between 8 and 9 a.m. Fasting concentrations of insulin was measured in mU/L. | Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial. | No |
Other | Other outcome was change in blood concentrations of LH (luteinizing hormone). | Patient's blood was drawn between 8 and 9 a.m. Concentration of LH was measured in U/L. | Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial. | No |
Other | Other outcome was change in blood concentrations of FSH (follicle-stimulating hormone). | Patient's blood was drawn between 8 and 9 a.m. Blood concentrations of FSH was measured in U/L. | Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial. | No |
Other | Other outcome was change in blood concentration of testosterone. | Patient's blood was drawn between 8 and 9 a.m. Blood concentration was measured in nmol/L. | Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial. | No |
Other | Other outcome was change in blood concentration in androstenedione. | Patient's blood was drawn between 8 and 9 a.m. Blood concentrations of androstenedione was measured in nmol/L. | Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial. | No |
Other | Other outcome was change in blood concentrations of SHBG (sex hormone-binding globulin). | Patient's blood was drawn between 8 and 9 a.m. Blood concentrations of SHBG was measured in nmol/L. | Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial. | No |
Other | Other outcome was change in blood concentration of DHEAS (dehydroepiandrosterone sulfate). | Patient's blood was drawn between 8 and 9 a.m. Blood concentrations of DHEAS was measured in micromol/L. | Patient's fasting blood was drawn at the base point and at the endpoint of 12 weeks of clinical trial. | No |
Primary | The main outcome was change in body weight. | The patient's body weight was measured in kilograms. | Patient's body weight was mesured at the base point and every four weeks during 12 weeks of clinical trial. | No |
Secondary | The secondary outcome was change in body mass index (BMI). | Patient's BMI was defined as the patient's body mass in kilograms divided by the square of their height in meters. | Patient's body weight were measured at the basepoint and every four weeks during the 12 weeks of clinical trial. Patient's height was measured at the basepoint. | No |
Secondary | The secondary outcome was change in waist circumference. | Patient's waist circumference was measured in centimeters. | Patient's waist circumference was measured at the basepoint and every four weeks during 12 weeks of clinical trial. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |